Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Antzeko izenburuak

• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  nork: Nishino, Mizuki, et al.
  Argitaratua: (2016)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  nork: Lo, Peter C., et al.
  Argitaratua: (2015)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  nork: Chaft, Jamie E., et al.
  Argitaratua: (2011)
• Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
  nork: Mak, Raymond H., et al.
  Argitaratua: (2011)
• Role of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
  nork: Mak, Raymond H., et al.
  Argitaratua: (2011)